Eli Lilly to stop developing schizophrenia drug
Aug 29 (Reuters) - Eli Lilly and Co said it would stop developing an experimental schizophrenia drug after a recent analysis showed that a late-stage trial on the drug was likely to fail.
Lilly said that an independent futility analysis concluded the second late-stage study on the drug was unlikely to meet the main goal of the trial.
Additionally, another mid-stage trial, which was testing the drug -- pomaglumetad methionil, or mGlu2/3 -- as an adjunctive treatment with atypical antipsychotics, also failed to meet the main study goal.
- Somali officials say U.S. struck where al Shabaab were meeting
- Marilyn Monroe sex film to be kept private |
- Ukraine accuses Russia of 'undisguised aggression' as rebels advance |
- Actress Jennifer Lawrence contacts authorities after nude photos hacked
- Risk appetite flickers as ECB bets hold down euro